JP5265887B2 - 白髪を処理するためのエラグ酸の使用 - Google Patents
白髪を処理するためのエラグ酸の使用 Download PDFInfo
- Publication number
- JP5265887B2 JP5265887B2 JP2007161727A JP2007161727A JP5265887B2 JP 5265887 B2 JP5265887 B2 JP 5265887B2 JP 2007161727 A JP2007161727 A JP 2007161727A JP 2007161727 A JP2007161727 A JP 2007161727A JP 5265887 B2 JP5265887 B2 JP 5265887B2
- Authority
- JP
- Japan
- Prior art keywords
- ellagic acid
- hair
- acid
- salts
- monoacylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004209 hair Anatomy 0.000 title claims description 66
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 title claims description 57
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 title claims description 51
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 title claims description 50
- 229920002079 Ellagic acid Polymers 0.000 title claims description 50
- 229960002852 ellagic acid Drugs 0.000 title claims description 50
- 235000004132 ellagic acid Nutrition 0.000 title claims description 50
- 239000000203 mixture Substances 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 32
- 229920000570 polyether Polymers 0.000 claims description 28
- 229910052751 metal Inorganic materials 0.000 claims description 25
- 239000002184 metal Substances 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 18
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 239000002537 cosmetic Substances 0.000 claims description 15
- 239000013543 active substance Substances 0.000 claims description 11
- 230000019612 pigmentation Effects 0.000 claims description 11
- 210000004761 scalp Anatomy 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- -1 nicotinic acid ester Chemical class 0.000 claims description 6
- 201000004384 Alopecia Diseases 0.000 claims description 5
- 206010040844 Skin exfoliation Diseases 0.000 claims description 5
- 230000035618 desquamation Effects 0.000 claims description 5
- 208000024963 hair loss Diseases 0.000 claims description 5
- 230000003676 hair loss Effects 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 5
- 238000011069 regeneration method Methods 0.000 claims description 5
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000002088 nanocapsule Substances 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims description 4
- 239000011664 nicotinic acid Substances 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000004005 microsphere Substances 0.000 claims description 3
- 239000002077 nanosphere Substances 0.000 claims description 3
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 2
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 claims description 2
- 229950004580 benzyl nicotinate Drugs 0.000 claims description 2
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 230000018109 developmental process Effects 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 229940081510 piroctone olamine Drugs 0.000 claims description 2
- 229910000338 selenium disulfide Inorganic materials 0.000 claims description 2
- JNMWHTHYDQTDQZ-UHFFFAOYSA-N selenium sulfide Chemical compound S=[Se]=S JNMWHTHYDQTDQZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960005265 selenium sulfide Drugs 0.000 claims description 2
- 229960002703 undecylenic acid Drugs 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 6
- OWEGWHBOCFMBLP-UHFFFAOYSA-N 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one Chemical compound C1=CN=CN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 OWEGWHBOCFMBLP-UHFFFAOYSA-N 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 229960003344 climbazole Drugs 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000003659 hair regrowth Effects 0.000 claims 1
- 210000002752 melanocyte Anatomy 0.000 description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 21
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 15
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 14
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 12
- 208000012641 Pigmentation disease Diseases 0.000 description 12
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 210000003780 hair follicle Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000006210 lotion Substances 0.000 description 8
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 7
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000002453 shampoo Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- AKZWRTCWNXHHFR-PDIZUQLASA-N [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(5S)-5-benzyl-3-[(2R)-2-carbamoyloxy-2,3-dihydro-1H-inden-1-yl]-4-oxo-3H-pyrrol-5-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical compound NC(=O)O[C@@H]1Cc2ccccc2C1C1C=N[C@](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CCOC2)(Cc2ccccc2)C1=O AKZWRTCWNXHHFR-PDIZUQLASA-N 0.000 description 5
- 150000004696 coordination complex Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 230000002087 whitening effect Effects 0.000 description 5
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 4
- YFTGOBNOJKXZJC-UHFFFAOYSA-N 5,6-dihydroxyindole-2-carboxylic acid Chemical compound OC1=C(O)C=C2NC(C(=O)O)=CC2=C1 YFTGOBNOJKXZJC-UHFFFAOYSA-N 0.000 description 4
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 4
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000003061 melanogenesis Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- YTKGAYFHUZTLCI-UHFFFAOYSA-N 3-hydroxy-2-iminopyrimidin-4-amine Chemical compound NC1=CC=NC(=N)N1O YTKGAYFHUZTLCI-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 239000007957 coemulsifier Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000003793 hair pigmentation Effects 0.000 description 2
- 210000004919 hair shaft Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- KSZFSNZOGAXEGH-BYPYZUCNSA-N (2s)-5-amino-2-(methylamino)-5-oxopentanoic acid Chemical compound CN[C@H](C(O)=O)CCC(N)=O KSZFSNZOGAXEGH-BYPYZUCNSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- SGNZYJXNUURYCH-UHFFFAOYSA-N 5,6-dihydroxyindole Chemical compound C1=C(O)C(O)=CC2=C1NC=C2 SGNZYJXNUURYCH-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- TVZCRIROJQEVOT-CABCVRRESA-N Cromakalim Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C#N)CCCC1=O TVZCRIROJQEVOT-CABCVRRESA-N 0.000 description 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000796203 Homo sapiens L-dopachrome tautomerase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001113425 Iridaceae Species 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical class NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 241000549556 Nanos Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Chemical class NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Chemical class OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 1
- 229940127343 Potassium Channel Agonists Drugs 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040825 Skin depigmentation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229950004210 cromakalim Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical group COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000000485 pigmenting effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 125000004402 polyphenol group Chemical group 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000004059 quinone derivatives Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000004511 skin melanocyte Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
- A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
− 皮膚細胞の分化及び/又は増殖及び/又は色素沈着を調節する薬剤、例えば、レチノール及びそのエステル、ビタミンD及びその誘導体、エストラジオールなどのエストロゲン、cAMPモジュレーター、例えば、POMC誘導体、アデノシン、又はフォルスコリン及びその誘導体、プロスタグランジン及びその誘導体、トリヨードトリオニン(triiodotrionine)及びその誘導体など;
− 植物抽出物、例えば、Iridaceae又は大豆由来のものなどであって、この抽出物には、その場合に、イソフラボンが含まれていても、又は含まれていなくてもよい;
− 微生物の抽出物:
− フリーラジカルスカベンジャー、例えば、α−トコフェロール若しくはそのエステル、スーパーオキシドジスムターゼ若しくは同種のもの、特定の金属キレート剤、又はアスコルビン酸及びそのエステル;
− 抗脂漏剤、例えば、特定の硫黄含有アミノ酸、13−cis−レチノイン酸、酢酸シプロテロン;
− 頭皮の落屑状態に対抗する他の薬剤、例えば、二硫化セレン、クリンバゾール、ウンデシレン酸、ケトコナゾール、ピロクトンオラミン(オクトピロックス)、又はシクロピロクトン(ciclopiroctone)(シクロピロックス);
特に、これらは、再生を刺激及び/又は脱毛の減速を促進する活性剤であってよく、非限定的な方法で、特に以下を挙げてよい:
− ニコチン酸エステル、特に、ニコチン酸トコフェリル、ニコチン酸ベンジル、及びC1〜C6のニコチン酸アルキル、例えば、ニコチン酸メチル又はニコチン酸ヘキシルなどを含む;
− ピリミジン誘導体、例えば、米国特許第4139619号及び同第4596812号に記載の2,4−ジアミノ−6−ピペリジノピリミジン3−オキシド又は「Minoxidil」;WO 96/09048に記載のAminexil又は2,4−ジアミノピリミジン3−オキシド;
− 毛髪再生を促進するリポキシゲナーゼ阻害剤又はシクロオキシダーゼ誘導剤、例えば、本出願人による欧州特許出願第0648488号に記載のもの;
− 抗菌剤、例えば、マクロライド、ピラノシド、及びテトラサイクリン、特にエリスロマイシン;
− カルシウムアンタゴニスト、例えば、シンナリジン、ニモジピン、及びニフェジピン;
− ホルモン、例えば、エストリオール若しくは同種のもの、又はチロキシン及びその塩;
− 抗アンドロゲン、例えば、オキセンドロン、スピロノラクトン、ジエチルスチルベストロール、及びフルタミド;
− 5−α−レダクターゼのステロイド又は非ステロイド阻害剤、例えば、本出願人による欧州特許出願第0964852号及び同第1068858号に記載のもの、又は他にフィナステリド;
− ATP依存性カリウムチャネルアゴニスト、例えば、クロマカリム及びニコランジル;並びに
− 色素沈着促進活性を有する植物抽出物、例えば、FR 2768343に記載のクリサンテマム(chrysanthemum)抽出物、及びFR 2782920に記載のSanguisorba抽出物。
[実施例1:エラグ酸によるメラノサイトの保護の実証]
(1−A−1.培養正常ヒトメラノサイト(NHM)における、H2O2ストレスにより産生される活性酸素種(ROS)を測定するためのプロトコル)
正常ヒトメラノサイト(NHM)を、4×104細胞/cm2の密度で、D0で播種した。D1時に、PBS中、6−カルボキシ−2',7'−ジクロロジヒドロフルオレセインジアセテート、ジ[アセトキシメチルエステル](H2DCFDA、C2938、Molecular Probe)の10μM溶液に培養媒体を取り換えた。20分後、H2DCFDA溶液を培養媒体と取り換えた。NHMを30分間放置し、その後H2O2溶液(250μM)を添加した。15分後、フルオロスキャン(励起:485 nm、発光:538 nm)でフルオレセインを測定した。
結果は、生のフルオレセインデータを表し、ここから、蛍光単位(fu)で表され、代表的実験の間に得られる「ブランク」細胞の自己蛍光値を差し引いた。
正常ヒトメラノサイト(NHM)を、4×104細胞/cm2の密度で、D0で播種した。細胞付着後(3時間)、研究する化合物を培養媒体に添加した。24〜48時間後、Alamar Blue(UP669413 UPTIMA, Interchim)を用いて、供給者の指示に従って細胞生存率を測定した。
結果は、代表的実験で得られ(3連測定)(2の独立実験を実施した)、研究する活性剤の濃度(μM)の関数としての%蛍光曲線の形態で示される、蛍光シグナルパーセンテージを表す。結果を図2に示す。
O. Toussaint, E.E. Medrano and T. von Zglinicki, Experimental Gerontology 2000, 35, 927−945による。
結果は、慢性H2O2ストレスによりin vitroで誘導される促進老化に対するエラグ酸(EA)の効果を明らかにし、エラグ酸の存在下での生存率の顕著な増加を示す。
Claims (9)
- 白髪の発生を予防するため及び/又は制限するため及び/又は停止させるための、エラグ酸、その塩、その金属錯体、そのモノエーテル又はポリエーテル、モノアシル化又はポリアシル化エラグ酸、あるいはカーボネート化又はカルバメート化エラグ酸の美容的使用。
- グレーの頭髪及び/又は体毛の自然な色素沈着を維持するため並びに/あるいは回復させるための、請求項1記載の使用。
- 前記エラグ酸、その塩、その金属錯体、そのモノエーテル又はポリエーテル、モノアシル化又はポリアシル化エラグ酸、あるいはカーボネート化又はカルバメート化エラグ酸が、局所的又は経口的手段により投与されることを特徴とする、請求項1又は2記載の使用。
- 前記エラグ酸、その塩、その金属錯体、そのモノエーテル又はポリエーテル、モノアシル化又はポリアシル化エラグ酸、あるいはカーボネート化又はカルバメート化エラグ酸が、頭皮の落屑状態に対抗するための薬剤、あるいは脱毛を減速させるか又はその再生を促進する薬剤から選択されるもう1つの活性剤と組み合わされることを特徴とする、請求項1乃至3のいずれか一項記載の使用。
- 化粧品として許容可能な媒体中に、エラグ酸、その塩、その金属錯体、そのモノエーテル又はポリエーテル、モノアシル化又はポリアシル化エラグ酸、あるいはカーボネート化又はカルバメート化エラグ酸から選択される少なくとも1つの化合物と、二硫化セレン、クリンバゾール、ウンデシレン酸、ケトコナゾール、ピロクトンオラミン、若しくはシクロピロクトンから選択される頭皮の落屑状態に対抗するための薬剤から選択されるもう1つの活性剤とを組み合わせて含む、白髪の発生を予防するため及び/又は制限するため及び/又は停止させるための化粧品組成物。
- 化粧品として許容可能な媒体中に、エラグ酸、その塩、その金属錯体、そのモノエーテル又はポリエーテル、モノアシル化又はポリアシル化エラグ酸、あるいはカーボネート化又はカルバメート化エラグ酸から選択される少なくとも1つの化合物と、ニコチン酸ベンジル及びC1〜C6のニコチン酸アルキルから選択されるニコチン酸エステル、並びに毛髪再生を促進するリポキシゲナーゼ阻害剤又はシクロオキシダーゼ誘導剤から選択される、脱毛を減速させるか又はその再生を促進する1つの薬剤とを組み合わせて含む、白髪の発生を予防するため及び/又は制限するため及び/又は停止させるための化粧品組成物。
- 前記化合物が、マイクロスフェア、ナノスフェア、オレオソーム、又はナノカプセルなどのコーティングでカプセル化されることを特徴とする、請求項5又は6記載の組成物。
- 頭皮及び/又は毛髪で覆われた皮膚の領域への局所適用に適することを特徴とする、請求項5乃至7のいずれか一項記載の組成物。
- エラグ酸、その塩、その金属錯体、そのモノエーテル又はポリエーテル、モノアシル化又はポリアシル化エラグ酸、あるいはカーボネート化又はカルバメート化エラグ酸から選択される化合物を含む組成物が、経口投与されるか、又は処理されるべき領域に局所適用されることを特徴とする、白髪の美容処理方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0652552A FR2902324B1 (fr) | 2006-06-20 | 2006-06-20 | Utilisation d'acide ellagique pour le traitement de la canitie |
FR0652552 | 2006-06-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008001693A JP2008001693A (ja) | 2008-01-10 |
JP5265887B2 true JP5265887B2 (ja) | 2013-08-14 |
Family
ID=37667229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007161727A Active JP5265887B2 (ja) | 2006-06-20 | 2007-06-19 | 白髪を処理するためのエラグ酸の使用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8895037B2 (ja) |
EP (1) | EP1870081B1 (ja) |
JP (1) | JP5265887B2 (ja) |
KR (2) | KR101089071B1 (ja) |
CN (1) | CN101116654B (ja) |
ES (1) | ES2404157T3 (ja) |
FR (1) | FR2902324B1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008008537A1 (de) * | 2008-02-06 | 2009-08-13 | Beiersdorf Ag | Wundversorgungsartikel |
FR2951938B1 (fr) * | 2009-10-30 | 2012-01-06 | Oreal | Utilisation d'un extrait de punica granatum pour lutter contre la canitie |
FR2951943B1 (fr) * | 2009-10-30 | 2015-08-21 | Oreal | Utilisation d'un extrait de rubus fructicosus pour lutter contre la canitie |
FR2951941B1 (fr) * | 2009-10-30 | 2012-01-06 | Oreal | Utilisation d'un extrait de rubus idaeus pour lutter contre la canitie |
FR2951942A1 (fr) * | 2009-10-30 | 2011-05-06 | Oreal | Utilisation d'un extrait de terminalia pour lutter contre la canitie |
FR2956809B1 (fr) * | 2010-03-01 | 2014-09-26 | Oreal | Composition comprenant de l'acide ellagique et un tensioactif cationique particulier et son utilisation en cosmetique |
US20130085177A1 (en) * | 2010-03-01 | 2013-04-04 | Tiphaine Derkx | Cosmetic composition based on ellagic acid or a derivative thereof and on a particular mixture of surfactants |
FR2956812B1 (fr) * | 2010-03-01 | 2013-03-08 | Oreal | Composition cosmetique a base d'acide ellagique ou d'un de ses derives et d'un extrait de bacterie. |
FR2956810B1 (fr) * | 2010-03-01 | 2013-04-12 | Oreal | Composition cosmetique a base d'acide ellagique ou d'un de ses derives et d'un melange particulier de tensioactifs anioniques et amphoteres ou zwitterioniques. |
FR2956811B1 (fr) * | 2010-03-01 | 2012-05-25 | Oreal | Composition cosmetique anti-pelliculaire a base d'acide ellagique ou d'un de ses derives et d'un second compose actif different dans un rapport ponderal particulier. |
FR2956808B1 (fr) * | 2010-03-01 | 2012-05-25 | Oreal | Utilisation de l'acide ellagique comme agent anti-pelliculaire. |
FR2959666B1 (fr) * | 2010-05-07 | 2012-07-20 | Oreal | Composition cosmetique moussante a base d'acide ellagique ou d'un de ses derives et d'huile essentielle. |
FR3000386A1 (fr) * | 2012-12-27 | 2014-07-04 | Oreal | Procede de coloration capillaire mettant en oeuvre un colorant chromenique ou chromanique et un acide polyphenolique particulier |
DE102014111357B4 (de) | 2014-08-08 | 2018-09-27 | Minasolve Germany Gmbh | Ellagsäure enthaltende Partikel und Verfahren zu ihrer Herstellung |
CN104825369B (zh) * | 2015-05-25 | 2018-01-12 | 广东药学院 | 一种兼具养发功效的纯天然植物染发剂及其制备方法 |
WO2017131001A1 (ja) * | 2016-01-25 | 2017-08-03 | サントリーホールディングス株式会社 | エラグ酸ゼラチンカプセルを含有する組成物 |
KR102430414B1 (ko) | 2017-09-08 | 2022-08-09 | 인하대학교 산학협력단 | 용안육 추출물 또는 이의 분획물을 유효성분으로 함유하는 백모증 치료 또는 예방용 약학적 조성물 |
CN109363987B (zh) * | 2018-11-15 | 2022-01-11 | 无限极(中国)有限公司 | 地榆提取物及其制备工艺和应用 |
CN117178035A (zh) | 2021-05-21 | 2023-12-05 | Dic株式会社 | 油墨组合物、光转换层、滤色器和光转换膜 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6479103A (en) * | 1987-06-09 | 1989-03-24 | Lion Corp | External preparation |
US5002785A (en) * | 1988-11-29 | 1991-03-26 | Lew Chel W | Method of making encapsulated food products |
FR2724561B1 (fr) * | 1994-09-19 | 1996-12-13 | Oreal | Utilisation du 2,4-diamino pyrimidine 3-oxyde ou de l'un de ses sels dans le traitement des desordres de la maturation et de la structuration du collagene |
CA2219605C (en) * | 1996-10-31 | 2002-02-05 | Deepa Ashok Khambe | Method of stimulating gastrointestinal motility with ellagic acid |
US6037326A (en) * | 1996-12-31 | 2000-03-14 | Styczynski; Peter | Reduction of hair growth |
FR2768927B1 (fr) * | 1997-10-01 | 2000-01-21 | Lvmh Rech | Utilisation de l'acide ellagique, de ses sels, de ses complexes metalliques, de ses derives mono- ou poly-ethers, mono- ou poly-acyles dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie |
JP3660485B2 (ja) * | 1997-10-17 | 2005-06-15 | 花王株式会社 | 白髪防止剤 |
FR2769854B1 (fr) * | 1997-10-21 | 2000-03-31 | Prographarm Lab | Nouveau procede d'obtention de microspheres et les produits ainsi realises |
JPH11322569A (ja) * | 1998-05-12 | 1999-11-24 | Lion Corp | 皮膚外用組成物 |
FR2782920B1 (fr) * | 1998-09-07 | 2000-10-06 | Oreal | Utilisation d'au moins un extrait de rosacee du genre sanguisorba officinalis pour favoriser la pigmentation de la peau et/ou des cheveux |
FR2804960B1 (fr) * | 2000-02-11 | 2005-06-24 | Lvmh Rech | Nouveaux oligonucleotides et utilisation d'oligonucleotides modulant l'expression de la tyrosinase et de la tyrosinase- related-protein 1 comme agents depigmentants |
JP2001302543A (ja) * | 2000-04-27 | 2001-10-31 | Lion Corp | 髪質改善剤 |
FR2809004B1 (fr) * | 2000-05-18 | 2002-12-27 | Oreal | Utilisation de l'acide ellagique comme agent cosmetique anti-pollution |
US6989161B2 (en) * | 2000-06-12 | 2006-01-24 | Access Business Group International Llc | Phytonutrient nutritional supplement |
JP2002012519A (ja) * | 2000-06-28 | 2002-01-15 | Lion Corp | 養育毛剤組成物 |
JP4627107B2 (ja) * | 2000-07-06 | 2011-02-09 | ライオン株式会社 | 毛髪外用剤組成物 |
US20040067245A1 (en) * | 2000-12-20 | 2004-04-08 | Harish Mahalingam | Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin |
US6387370B1 (en) * | 2001-01-19 | 2002-05-14 | A. Glenn Braswell | Compositions containing extracts of Morinda citrifolia, red wine, prune, blueberry, pomegranate, apple and enzyme mixture |
US20020127256A1 (en) * | 2001-03-01 | 2002-09-12 | Howard Murad | Compositions and methods for treating dermatological disorders |
WO2003026598A1 (fr) * | 2001-09-19 | 2003-04-03 | Lion Corporation | Preparation externe |
FR2832630B1 (fr) * | 2001-11-28 | 2005-01-14 | Oreal | Composition cosmetique et/ou dermatologique contenant au moins un actif hydrophile sensible a l'oxydation stabilise par au moins un copolymere de n-vinylimidazole |
JP4076477B2 (ja) * | 2003-05-28 | 2008-04-16 | 株式会社クラレ | 皮膚外用剤 |
WO2005006879A2 (en) * | 2003-07-03 | 2005-01-27 | California Giant, Inc. | Nutritious strawberry fruit juice drink and method of making the same |
JP4182348B2 (ja) * | 2003-09-08 | 2008-11-19 | ライオン株式会社 | 化粧料組成物及びその製造方法 |
US20060251753A1 (en) * | 2005-05-09 | 2006-11-09 | Ahmad Alkayali | Ellagic acid food supplement prepared from pomegranate seed |
-
2006
- 2006-06-20 FR FR0652552A patent/FR2902324B1/fr not_active Expired - Fee Related
-
2007
- 2007-06-06 ES ES07109693T patent/ES2404157T3/es active Active
- 2007-06-06 EP EP07109693A patent/EP1870081B1/fr active Active
- 2007-06-19 JP JP2007161727A patent/JP5265887B2/ja active Active
- 2007-06-19 CN CN2007101362870A patent/CN101116654B/zh active Active
- 2007-06-20 US US11/812,572 patent/US8895037B2/en active Active
- 2007-06-20 KR KR1020070060436A patent/KR101089071B1/ko active IP Right Grant
-
2009
- 2009-10-15 KR KR1020090098234A patent/KR20090115841A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR101089071B1 (ko) | 2011-12-05 |
US20080026019A1 (en) | 2008-01-31 |
FR2902324A1 (fr) | 2007-12-21 |
FR2902324B1 (fr) | 2009-04-03 |
EP1870081B1 (fr) | 2013-02-13 |
KR20070120906A (ko) | 2007-12-26 |
ES2404157T3 (es) | 2013-05-24 |
CN101116654B (zh) | 2012-11-21 |
EP1870081A1 (fr) | 2007-12-26 |
KR20090115841A (ko) | 2009-11-09 |
CN101116654A (zh) | 2008-02-06 |
JP2008001693A (ja) | 2008-01-10 |
US8895037B2 (en) | 2014-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5265887B2 (ja) | 白髪を処理するためのエラグ酸の使用 | |
JP4971072B2 (ja) | 毛包メラノサイトの保護剤としてのドーパクローム異性化酵素(trp−2)活性を真似る薬剤の使用とその使用 | |
KR100930257B1 (ko) | 백모증 처리를 위한, 3h-1,2-디티올-3-티온, 아네톨 디티올에티온, 설포라판, 펜에틸 이소티오시아네이트, 6-(메틸설피닐)헥실 이소티오시아네이트 및 알릴 이소티오시아네이트의 용도 | |
JP2005537332A (ja) | 新規ノルアポルフィン誘導体 | |
US8969407B2 (en) | Administration of coumarin, butylated hydroxyanisole and ethoxyquine for the treatment of canities | |
EP1830825A1 (fr) | Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie | |
FR2939030A1 (fr) | Utilisation de la taurine pour le traitement de la canitie | |
FR2902320A1 (fr) | Utilisation de butylated hydroxyanisole pour le traitement de la canitie | |
JP5669436B2 (ja) | 組成物 | |
ES2447853T3 (es) | Utilización de un agente inductor de la expresión de la DOPAcromo tautomerasa (TRP-2) como agente protector de los melanocitos del folículo piloso | |
JP2011241164A5 (ja) | ||
FR2902321A1 (fr) | Utilisation de curcumin pour le traitement de la canitie | |
FR2902329A1 (fr) | Utilisation de sulforaphane, de phenethyl isothiocyanate, de 6-methyl-sulphinyl)hexyl isothiocyanate et d'allyl isothiocyanate pour le traitement de la canitie. | |
FR2908652A1 (fr) | Utilisation d'ethoxuquine pour le traitement de la canitie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100405 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120612 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120717 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121017 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121022 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121119 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121217 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130115 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130402 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130502 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5265887 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |